ROCKVILLE, Md.--(BUSINESS WIRE)--Mar. 8, 2012-- Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the fourth quarter and full year ended December 31, 2011. Total revenues for 2011 were $273.4 million as compared to $286.2 million in 2010, and net income for 2011 was $23.0 million, or $0.65 per basic share, as compared to $51.7 million, or $1.63 per basic share, in 2010.
ROCKVILLE, Md., Apr 26, 2012 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) today announced its support of the North Atlantic Treaty Organization (NATO) Emerging Security Challenges Division (ESCD) in hosting a biopreparedness workshop entitled "A Bio-Attack: Are We Prepared?" The workshop aims to evaluate and strengthen NATO's strategies and capabilities in managing consequences of potential chemical, biological, radiological, and nuclear attacks.
BIO International Convention
San Diego, CA
Emergent Investigator Community
To join the Emergent investigator community, please fill out and submit the form below:
New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial in